Список литературы к Главе 7

29. Solh M., Rai K.R., Peterson B.L. et al. The impact of initial fludarabine therapy on transformation to Richter’s syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011) // Leuk. Lymphoma. 2013. Vol. 54. P. 252–254.

30. Fischer K., Bahlo J., Fink A.M. et al. Long­term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.

31. Byrd J.C., Furman R.R., Coutre S.E. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369. P. 32–42.

32. Byrd J.C., Brown J.R., O’Brien S. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia // N. Engl. J. Med. 2014. Vol. 371. P. 213–223.

33. O’Brien S., Furman R.R., Coutre S.E. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open­label, multicentre, phase 1b/2 trial // Lancet Oncol. 2014. Vol. 15. P. 48–58.

34. Strati P., Keating M.J., O’Brien S.M. et al. Outcomes of first­line treatment for chronic lymphocytic leukemia with 17p deletion // Haematologica. 2014. Vol. 99. P. 1350–1355.

35. Farooqui M.Z., Valdez J., Martyr S. et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single­arm trial // Lancet Oncol. 2015. Vol. 16. P. 169–176.

36. Jain P., Keating M., Wierda W. et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib // Blood. 2015. Vol. 125. P. 2062–2067.

37. Mato A.R., Nabhan C., Barr P.M. et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience // Blood. 2016. Vol. 128, N 18. P. 2199–2205.

38. Roberts A.W., Davids M.S., Pagel J.M. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 311–322.

39. Furman R.R., Sharman J.P., Coutre S.E. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2014. Vol. 370, N 11. P. 997–1007.

40. Seymour J.F., Kipps T.J., Eichhorst B.F. et al. Venetoclax Plus Rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia – results from pre­planned interim analysis of the randomized phase 3 MURANO study // Blood. 2017. Vol. 130. Abstr. LBA­2.

41. Khan M., Siddiqi R., Thompson R.A. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies // Ann. Hematol. 2018. Vol. 97, N 1. P. 1–15.

42. Robertson L.E., Pugh W., O’Brien S. et al. Richter’s syndrome: a report on 39 patients // J. Clin. Oncol. 1993. Vol. 11. P. 1985–1989.

43. Bruzzi J.F., Macapinlac H., Tsimberidou A.M. et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT // J. Nucl. Med. 2006. Vol. 47. P. 1267–1273.

44. Falchi L., Keating M.J., Marom E.M. et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia // Blood. 2014. Vol. 123, N 18. P. 2783–2790.

45. Mauro F.R., Chauvie S., Paoloni F. et al. Diagnostic and prognostic role of ПЭТ/КТ in patients with chronic lymphocytic leukemia and progressive disease // Leukemia. 2015. Vol. 29, N 6. P. 1360–1365.

46. Rogers K.A., Huang Y., Ruppert A.S. et al. A single­institution retrospective cohort study of first­line R­EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor // Br. J. Haematol. 2018. Vol. 180, N 2. P. 259–266. DOI: https://doi.org/10.1111/bjh.15035

47. Mato A.R., Wierda W.G., Davids M.S. et al. Analysis of PET­CT to identify Richter’s transformation in 167 patients with disease progression following kinase inhibitor therapy // Blood. 2017. Vol. 130. P. 834.

48. Porrazzo M., Nicolai E., Riminucci M. et al. Prognostic significance of ПЭТ/КТ in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy // Cancers (Basel). 2020. Vol. 12, N 7. P. 1773.

49. Gascoyne R.D. XIV. The pathology of transformation of indolent B cell lymphomas // Hematol. Oncol. 2015. Vol. 33, suppl. 1. P. 75–79.

50. Tsimberidou A.­M., O’Brien S., Khouri I. et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem­cell transplantation // J. Clin. Oncol. 2006. Vol. 24. P. 2343–2351.

51. Abrisqueta P., Delgado J., Alcoceba M. et al. Clinical outcome and prognostic factors of patients with Richter’s syndrome: retrospective multicenter study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC) // Blood. 2017. Vol. 130. P. 2995.

52. Parikh S.A., Kay N.E., Shanafelt T.D. How we treat Richter syndrome // Blood. 2014. Vol. 123, N 11. P. 1647–1657.

53. Jain P., Thompson P.A., Keating M. et al. Long­term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib // Cancer. 2017. Vol. 123, N 12. P. 2268–2273. DOI: https://doi.org/10.1002/cncr.30596.

54. Byrd J.C., Blum K.A., Burger J.A. et al. Activity and tolerability of the Bruton’s tyrosine kinase (Btk) inhibitor PCI­32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study // J. Clin. Oncol. 2011. Vol. 29, N 15. Suppl. P. 6508–6508.

55. Langerbeins P., Busch R., Anheier N. et al. Poor efficacy and tolerability of R­CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation // Am. J. Hematol. 2014. Vol. 89. P. E239–E243.

56. Eyre T.A., Clifford R., Bloor A. et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome // Br. J. Haematol. 2016. Vol. 175, N 1. P. 43–54.

57. Tsimberidou A.M., Wierda W.G., Plunkett W. et al. Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine­refractory chronic lymphocytic leukemia // J. Clin. Oncol. 2008. Vol. 26. P. 196–203.

58. Tsimberidou A.M., Wierda W.G., Wen S. et al. Phase I­II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome // Clin. Lymphoma Myeloma Leuk. 2013. Vol. 13. P. 568–574.

59. Durot E., Michallet A.S., Leprêtre S., Le Q.H., Leblond V., Delmer A. Platinum and high­dose cytarabine­based regimens are efficient in ultra high/high­risk chronic lymphocytic leukemia and Richter’s syndrome: results of a French retrospective multicenter study // Eur. J. Haematol. 2015. Vol. 95, N 2. P. 160–167.

60. Dabaja B.S., O’Brien S.M., Kantarjian H.M. et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyper­CVXD) regimen in Richter’s syndrome // Leuk. Lymphoma. 2001. Vol. 42. P. 329–337.

61. Tsimberidou A.M., Kantarjian H.M., Cortes J. et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocytemacrophage­ colony stimulating factor (GM­CSF) alternating with methotrexate and cytarabine plus rituximab and GMCSF in patients with Richter syndrome or fludarabine refractory chronic lymphocytic leukemia // Cancer. 2003. Vol. 97. P. 1711–1720.

62. Cwynarski K., Van Biezen A., De Wreede L. et al. Autologous and allogeneic stem­cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation // J. Clin. Oncol. 2012. Vol. 30. P. 2211–2217.

63. Tsang M., Shanafelt T.D., Call T.G. et al. The efficacy of ibrutinib in the treatment of Richter syndrome // Blood. 2015. Vol. 125, N 10. P. 1676-1678.

64. Hillmen P., Schuh A., Eyre T.A. et al. Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE­CL­001 clinical study // Blood. 2016. Vol. 128. P. 2260.

65. Davids M.S., Roberts A.W., Seymour J.F. et al. Phase I First­in­human study of venetoclax in patients with relapsed or refractory non­Hodgkin lymphoma // J. Clin. Oncol. 2017. Vol. 35, N 8. P. 826–833.

66. Kuruvilla J., Savona M., Baz R. et al. Selective inhibition of nuclear export with selinexor in patients with non­Hodgkin lymphoma // Blood. 2017. Vol. 129, N 24. P. 3175–3183.

67. Ding W., LaPlant B.R., Call T.G. et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL // Blood. 2017. Vol. 129, N 26. P. 3419–3427.

68. Jain N., Basu S., Thompson P.A. et al. Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial // Blood. 2016. Vol. 128. P. 59.

69. Leiming X., Qian C., Qiao L., Tan L., Yi W., Yangyi B. The clinical study on CD19­directed chimeric antigen receptor­modified T cells in patient with Richter syndrome. DOI: https://doi.org/10.1158/1538­7445.AM2017­CT041

70. Evans A., Burack R., Rothberg P.G., Porter D., Liesveld J.L. Evolution to plasmablastic lymphoma (PBL) after CAR­T cell therapy in a case of SLL/CLL with Richter’s transformation // Blood. 2014. Vol. 124. P. 5660.

71. Gaidano G., Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment // Hematology Am. Soc. Hematol. Educ. Program. 2017. Vol. 2017, N 1. P. 329–337.

72. Parikh S.A., Habermann T.M., Chaffee K.G. et al. Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma // Am. J. Hematol. 2015. Vol. 90, N 4. P. 334–338.

73. Tsimberidou A.M., O’Brien S., Kantarjian H.M. et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience // Cancer. 2006. Vol. 107. P. 1294–1302.

74. Bockorny B., Codreanu I., Dasanu C.A. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature // Br. J. Haematol. 2012. Vol. 156. P. 50–66.

75. Tadmor T., Shvidel L., Goldschmidt N. et al. Hodgkin’s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group // Anticancer Res. 2014. Vol. 34. P. 785–790.

76. Moia R., Patriarca A., Schipani M. et al. Precision medicine management of chronic lymphocytic leukemia // Cancers (Basel). 2020. Vol. 12, N 3. P. 642.

77. Moia R., Patriarca A., Deambrogic C. et al. An update on: molecular genetics of high risk chronic lymphocytic leukemia // Exp. Rev. Hematol. 2020. Vol. 13, N 2. P. 109–116.

78. Diop F., Moia R., Favini C. et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia // Haematologica. 2020. Vol. 105, N 2. P. 448–456.

79. Moia R., Patriarca A., Mahmoud A.M. et al. Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics // Exp. Opin. Orphan. Drugs. 2020. DOI: https://doi.org/10.1080/21678707.2020.1804860